| human | Q5 |
| P106 | occupation | author | Q482980 |
| Q104755712 | A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation |
| Q33930593 | Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. |
| Q61899178 | Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma |
| Q36180225 | Adjuvant treatment of malignant melanoma: where are we? |
| Q55673215 | Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. |
| Q91323560 | Anti-PD-1 and PD-L1 antibodies in metastatic melanoma |
| Q64926172 | Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. |
| Q37102302 | Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma |
| Q35798996 | Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy |
| Q40226135 | Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. |
| Q40506025 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab |
| Q62661800 | Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab |
| Q56891361 | CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab |
| Q30828178 | Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort |
| Q37809159 | Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies |
| Q35496973 | Clinicopathologic features and surgical management of primary umbilical melanoma: a case series. |
| Q39069585 | Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care |
| Q45904354 | Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters. |
| Q33433902 | Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib |
| Q51529309 | Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. |
| Q51958698 | Computer-aided diagnosis of melanocytic lesions. |
| Q45896397 | Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients |
| Q45907075 | Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. |
| Q38839130 | Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma |
| Q52659362 | Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. |
| Q41051660 | Do BRAF inhibitors select for populations with different disease progression kinetics? |
| Q33620317 | Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases |
| Q45904329 | Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg. |
| Q33604418 | Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. |
| Q91323356 | Electrochemotherapy in melanoma patients: a single institution experience |
| Q57781468 | Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma |
| Q63247804 | Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma |
| Q48244625 | FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. |
| Q44665315 | Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy |
| Q43159409 | Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial |
| Q59395466 | High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab |
| Q40287687 | Human melanoma metastases express functional CXCR4. |
| Q45765887 | IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients |
| Q57781473 | Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma |
| Q38004628 | Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. |
| Q53536244 | Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. |
| Q49658357 | Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. |
| Q92220421 | Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management |
| Q100629542 | Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists |
| Q38195330 | Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon |
| Q33402830 | Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial |
| Q34449037 | Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis |
| Q45904236 | Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma. |
| Q36972613 | Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients |
| Q38679954 | MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors |
| Q45904257 | MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab. |
| Q38164605 | Marker utility for combination therapy |
| Q36175784 | Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report |
| Q35916805 | Nevoid melanoma of the vagina: report of one case diagnosed on thin layer cytological preparations |
| Q90769008 | Nivolumab for the treatment of small cell lung cancer |
| Q26801752 | Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway |
| Q62661814 | PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab |
| Q52731766 | PD-L1 inhibitors in the pipeline: Promise and progress. |
| Q46761570 | Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies |
| Q34655046 | Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma |
| Q36687470 | Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma |
| Q64103569 | Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations |
| Q34114136 | Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment |
| Q36298852 | Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. |
| Q30746423 | Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program |
| Q33263686 | Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma |
| Q33877109 | Serious haematological toxicity during and after ipilimumab treatment: a case series. |
| Q57475128 | Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study |
| Q63247800 | Soluble interleukin-2 receptor in stage I–III melanoma |
| Q94483861 | Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer |
| Q46576244 | Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification |
| Q45904322 | Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. |
| Q46467240 | Temozolomide and cisplatin in avdanced malignant melanoma. |
| Q46574628 | The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg |
| Q34637951 | The role of BRAF V600 mutation in melanoma |
| Q38178089 | The role of MEK inhibitors in the treatment of metastatic melanoma |
| Q33657461 | The role of spectrophotometry in the diagnosis of melanoma |
| Q38289557 | The use of interferon in melanoma patients: a systematic review |
| Q38044882 | Update on PEG-interferon α-2b as adjuvant therapy in melanoma |
| Q48359916 | Vemurafenib beyond progression in a patient with metastatic melanoma: a case report |
| Q39009684 | Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. |
| Q64967605 | Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. |
| Q100419264 | [Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease] |
Search more.